Evrópusambandið - íslenska - EMA (European Medicines Agency)

ratiopharm gmbh - paklitaxel - brjóstakrabbamein - Æxlishemjandi lyf - pazenir sér er ætlað fyrir meðferð brjóstakrabbamein í fullorðinn sjúklingum sem hafa mistekist fyrsta lína meðferð fyrir sjúklingum sjúkdómur og fyrir hvern standard, anthracycline inniheldur meðferð er ekki ætlað. pazenir ásamt carboplatín er ætlað fyrir fyrsta lína meðferð ekki lítið klefi lungnakrabbamein í fullorðinn sjúklingum sem eru ekki mönnum fyrir hugsanlega læknandi skurðaðgerð og/eða geislameðferð.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft rejection - Ónæmisbælandi lyf - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - Ónæmisbælandi lyf - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) er ætlað fyrir meðferð fullorðinn sjúklinga með áður ómeðhöndlað margar forráðamenn sem eru ekki rétt fyrir ígræðslu. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) er ætlað fyrir meðferð fullorðinn sjúklinga með áður ómeðhöndlað margar forráðamenn sem eru ekki rétt fyrir ígræðslu. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim international gmbh* - alteplasum inn - stungulyfs-/innrennslisstofn og leysir, lausn

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cheplapharm arzneimittel gmbh - alfacalcidolum inn - mjúkt hylki - 0,25 míkróg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cheplapharm arzneimittel gmbh - alfacalcidolum inn - mjúkt hylki - 1 míkróg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid breytandi lyf - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Æxlishemjandi lyf - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - pamidronat dínatríum - innrennslisþykkni, lausn - 9 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - pamidronat dínatríum - innrennslisþykkni, lausn - 6 mg/ml